Protein biomarkerek szerepe a koponyasérüles kísérletes modelljeiben és a klinikumban.

Translated title of the contribution: Protein biomarkers in experimental models and in clinical care of traumatic brain injury

Jááos Lückl, O. Farkas, J. Pál, Erzsébet Kövesdi, Endre Czeiter, Dóra Szellár, T. Dóczi, S. Komoly, A. Büki

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Traumatic brain injury is the leading cause of mortality in Hungary in the population under 40 years of age. In Western societies, like the United Sates, traumatic brain injury represents an extreme social-economic burden, expected to become the third leading cause of mortality until 2020. Despite its' epidemiological significance, experimental therapeutic modalities developed in the last few decades did not prove efficient in the clinical care of severe traumatic brain injury. The reason for such a lack of success in terms of translating experimental results to clinical treatment at least partially could be explained by the paucity and the low sensitivity and specificity of clinical parameters endowing us to monitor the efficacy of the therapy. The drive for finding clinical parameters and monitoring tools that enable us to monitor treatment efficacy as well as outcome focused recent attention on biomarkers (and) surrogate markers that are based on rational pathological processes associated with/operant in traumatic brain injury. This review summarizes those biomarkers that could purportedly be used to monitor the treatment of the severely head injured while also providing information on salvageability facilitating the conduction of more rationally designed clinical studies.

Original languageHungarian
Pages (from-to)284-294
Number of pages11
JournalIdeggyógyászati szemle
Volume60
Issue number7-8
Publication statusPublished - Jul 30 2007

Fingerprint

Theoretical Models
Biomarkers
Proteins
Mortality
Hungary
Pathologic Processes
Head
Economics
Sensitivity and Specificity
Traumatic Brain Injury
Therapeutics
Population

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Protein biomarkerek szerepe a koponyasérüles kísérletes modelljeiben és a klinikumban. / Lückl, Jááos; Farkas, O.; Pál, J.; Kövesdi, Erzsébet; Czeiter, Endre; Szellár, Dóra; Dóczi, T.; Komoly, S.; Büki, A.

In: Ideggyógyászati szemle, Vol. 60, No. 7-8, 30.07.2007, p. 284-294.

Research output: Contribution to journalArticle

Lückl, Jááos ; Farkas, O. ; Pál, J. ; Kövesdi, Erzsébet ; Czeiter, Endre ; Szellár, Dóra ; Dóczi, T. ; Komoly, S. ; Büki, A. / Protein biomarkerek szerepe a koponyasérüles kísérletes modelljeiben és a klinikumban. In: Ideggyógyászati szemle. 2007 ; Vol. 60, No. 7-8. pp. 284-294.
@article{0f4a2814d71f418fbbf62548515468f7,
title = "Protein biomarkerek szerepe a koponyas{\'e}r{\"u}les k{\'i}s{\'e}rletes modelljeiben {\'e}s a klinikumban.",
abstract = "Traumatic brain injury is the leading cause of mortality in Hungary in the population under 40 years of age. In Western societies, like the United Sates, traumatic brain injury represents an extreme social-economic burden, expected to become the third leading cause of mortality until 2020. Despite its' epidemiological significance, experimental therapeutic modalities developed in the last few decades did not prove efficient in the clinical care of severe traumatic brain injury. The reason for such a lack of success in terms of translating experimental results to clinical treatment at least partially could be explained by the paucity and the low sensitivity and specificity of clinical parameters endowing us to monitor the efficacy of the therapy. The drive for finding clinical parameters and monitoring tools that enable us to monitor treatment efficacy as well as outcome focused recent attention on biomarkers (and) surrogate markers that are based on rational pathological processes associated with/operant in traumatic brain injury. This review summarizes those biomarkers that could purportedly be used to monitor the treatment of the severely head injured while also providing information on salvageability facilitating the conduction of more rationally designed clinical studies.",
author = "J{\'a}{\'a}os L{\"u}ckl and O. Farkas and J. P{\'a}l and Erzs{\'e}bet K{\"o}vesdi and Endre Czeiter and D{\'o}ra Szell{\'a}r and T. D{\'o}czi and S. Komoly and A. B{\"u}ki",
year = "2007",
month = "7",
day = "30",
language = "Hungarian",
volume = "60",
pages = "284--294",
journal = "Ideggyogyaszati Szemle",
issn = "0019-1442",
publisher = "Ifjusagi Lap-es Konyvkiado Vallalat",
number = "7-8",

}

TY - JOUR

T1 - Protein biomarkerek szerepe a koponyasérüles kísérletes modelljeiben és a klinikumban.

AU - Lückl, Jááos

AU - Farkas, O.

AU - Pál, J.

AU - Kövesdi, Erzsébet

AU - Czeiter, Endre

AU - Szellár, Dóra

AU - Dóczi, T.

AU - Komoly, S.

AU - Büki, A.

PY - 2007/7/30

Y1 - 2007/7/30

N2 - Traumatic brain injury is the leading cause of mortality in Hungary in the population under 40 years of age. In Western societies, like the United Sates, traumatic brain injury represents an extreme social-economic burden, expected to become the third leading cause of mortality until 2020. Despite its' epidemiological significance, experimental therapeutic modalities developed in the last few decades did not prove efficient in the clinical care of severe traumatic brain injury. The reason for such a lack of success in terms of translating experimental results to clinical treatment at least partially could be explained by the paucity and the low sensitivity and specificity of clinical parameters endowing us to monitor the efficacy of the therapy. The drive for finding clinical parameters and monitoring tools that enable us to monitor treatment efficacy as well as outcome focused recent attention on biomarkers (and) surrogate markers that are based on rational pathological processes associated with/operant in traumatic brain injury. This review summarizes those biomarkers that could purportedly be used to monitor the treatment of the severely head injured while also providing information on salvageability facilitating the conduction of more rationally designed clinical studies.

AB - Traumatic brain injury is the leading cause of mortality in Hungary in the population under 40 years of age. In Western societies, like the United Sates, traumatic brain injury represents an extreme social-economic burden, expected to become the third leading cause of mortality until 2020. Despite its' epidemiological significance, experimental therapeutic modalities developed in the last few decades did not prove efficient in the clinical care of severe traumatic brain injury. The reason for such a lack of success in terms of translating experimental results to clinical treatment at least partially could be explained by the paucity and the low sensitivity and specificity of clinical parameters endowing us to monitor the efficacy of the therapy. The drive for finding clinical parameters and monitoring tools that enable us to monitor treatment efficacy as well as outcome focused recent attention on biomarkers (and) surrogate markers that are based on rational pathological processes associated with/operant in traumatic brain injury. This review summarizes those biomarkers that could purportedly be used to monitor the treatment of the severely head injured while also providing information on salvageability facilitating the conduction of more rationally designed clinical studies.

UR - http://www.scopus.com/inward/record.url?scp=34548425148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548425148&partnerID=8YFLogxK

M3 - Article

C2 - 17713109

AN - SCOPUS:34548425148

VL - 60

SP - 284

EP - 294

JO - Ideggyogyaszati Szemle

JF - Ideggyogyaszati Szemle

SN - 0019-1442

IS - 7-8

ER -